SwissMedic-2021-0049-V449

Type IB variation for application SwissMedic-2021-0049. Type IB variation: Labeling Change for Atezolimumab-R — critical change

Variation Number
SwissMedic-2021-0049-V449
Type
Type IB
Application
SwissMedic-2021-0049
Change
CHG-2024-0149
Status
Overdue
Fee
€1,710
Submitted
2023-05-08
Approved
—
Description

Type IB variation: Labeling Change for Atezolimumab-R — critical change